Active RRMS Patients Treated with Alemtuzumab Experience Durable Reductions in MRI Disease Activity and Slowing of Brain Volume Loss: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (P6.367)
Year: 2018
Type: article
Source: Neurology
Institutions: University of Southern California, University of British Columbia, The University of Sydney, Vita-Salute San Raffaele University, Université de Strasbourg, Vall d'Hebron Hospital Universitari, University of Zurich, University Hospital Zurich, Cleveland Clinic, Montreal Neurological Institute and Hospital, NeuroRx Research (Canada), McGill University
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2883731232
